India has approved its first dengue vaccine, marking a significant milestone in the country’s fight against one of its fastest-growing mosquito-borne diseases. The Drug Controller General of India (DCGI) has granted marketing authorisation to Takeda’s QDENGA (TAK-003), making it the first dengue vaccine to receive regulatory approval in the country.
The approval comes as dengue continues to expand across India. According to Takeda, reported dengue cases in the country have increased more than 11-fold over the past two decades, with India accounting for nearly one-third of the global disease burden. Dengue has also surged worldwide, with record cases reported in 2024.
Why QDENGA Is Different
QDENGA is a tetravalent live-attenuated vaccine designed to protect against all four dengue virus serotypes. It has been approved in India for individuals aged 4 to 60 years and can be administered regardless of whether a person has previously been infected with dengue, eliminating the need for pre-vaccination screening.
This distinguishes it from Sanofi’s Dengvaxia, which is recommended only for people with a confirmed previous dengue infection because of safety considerations. By removing the need for routine serological testing, QDENGA could be easier to deploy across India’s large and diverse population.
Clinical data have also been encouraging. According to Takeda, QDENGA demonstrated 80.2% efficacy against confirmed dengue one year after the second dose and 90.4% efficacy against hospitalisation after 18 months.
India’s Vaccine Role
The approval also carries important manufacturing implications.
In February 2024, Takeda partnered with Hyderabad-based Biological E to expand global production of QDENGA. Under the agreement, Biological E is expected to manufacture up to 50 million doses annually, contributing towards Takeda’s goal of producing 100 million doses each year by 2030.
The collaboration reinforces India’s position as one of the world’s leading vaccine manufacturing hubs. If production scales as planned, it is expected to strengthen global vaccine supply while improving access across dengue-endemic countries.
The opportunity expanded further after the World Health Organization (WHO) prequalified QDENGA in May 2024, allowing United Nations agencies and Gavi-supported procurement programmes to purchase the vaccine for eligible countries.
Rollout Details Yet to Be Announced
Although regulatory approval marks an important breakthrough, several key questions remain.
Takeda has not announced when QDENGA will become commercially available in India or how much it will cost. Likewise, the Union Health Ministry has not indicated whether the vaccine will eventually be included in the Universal Immunisation Programme or any government-funded vaccination initiative.
Such decisions typically depend on disease burden, cost-effectiveness assessments, budget allocations and recommendations from public health experts.
For now, vaccination is expected to complement existing dengue control measures rather than replace them. Experts emphasise that mosquito control, disease surveillance, early diagnosis and public awareness will remain central to reducing dengue transmission, as vaccination alone cannot eliminate outbreaks while mosquitoes continue to spread the virus.
Expanding Global Footprint
India’s approval adds to QDENGA’s growing international presence.
According to Takeda, the vaccine has now been approved in 43 countries, with more than 32 million doses distributed worldwide since its launch in 2022.
For Takeda, the approval opens access to one of the world’s largest dengue-endemic markets while strengthening its manufacturing partnership with an Indian vaccine producer.
For India, it represents another step in its evolution from a supplier of routine vaccines to an increasingly important manufacturing base for next-generation vaccines addressing global public health challenges.
The long-term impact will depend on affordability, manufacturing capacity and future policy decisions. Nevertheless, the DCGI’s approval of QDENGA marks a significant regulatory milestone that could strengthen both India’s dengue prevention efforts and its role in the global vaccine ecosystem.
The Logical Indian’s Perspective
India’s first approved dengue vaccine is an important scientific and public health milestone, but its success will ultimately depend on equitable access, affordability and evidence-based policymaking. Vaccination should strengthen, not replace, existing efforts such as mosquito control, public awareness and timely healthcare.
As climate change, urbanisation and changing mosquito habitats increase the risk of vector-borne diseases, sustained investment in prevention, research and accessible healthcare will be essential. Scientific innovation creates lasting impact only when its benefits reach every community.
Also Read: CCPA Cracks Down On Chaayos, Barbeque Nation And 39 More Restaurants Over Service Charges
